enGene Therapeutics Inc. (ENGNW) Free cash flow 2022–2025
enGene Therapeutics Inc. (ENGNW) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$100.7MFY2025 · since FY2022: -$17.7M → -$100.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$100.7M | -104.7% |
| FY2024 | -$49.2M | -96.3% |
| FY2023 | -$25.1M | -41.2% |
| FY2022 | -$17.7M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More ENGNW financial trends
ENGNW RevenueENGNW Net incomeENGNW Net marginENGNW Gross profitENGNW Gross marginENGNW Operating incomeENGNW Operating marginENGNW Operating cash flowENGNW Capital expendituresENGNW Return on equityENGNW Stock buybacksENGNW Dividends paidENGNW Total assetsENGNW Total liabilitiesENGNW Shareholders’ equityENGNW overview →